Key Highlights
- Healthcare | ImmuPharma plc — LSE:IMM fell 17.04% on September 24, 2026, making it one of the notable healthcare decliners in the trading data provided.
- The company remains focused on two principal development programmes: P140, its lead autoimmune-focused asset, and Kapiglucagon, which is progressing through preclinical and regulatory preparation.
- ImmuPharma recently filed an international Patent application for P140 and its Type M precision-medicine approach, expanding its intellectual-property strategy.
- The company also reported additional peer-reviewed research involving P140, including activity in a preclinical model of metabolic dysfunction-associated steatohepatitis.
- ImmuPharma reported an operating loss of £1.1 million for the six months ended June 30, 2026, compared with £1.2 million a year earlier. The overall reported loss increased to £4.7 million, largely because of a £3.36 million finance loss related to the fair-value calculation of a derivative financial asset.
- The company completed an approximately £6.47 million fundraising in April 2026, with management stating that the financing and existing resources were expected to provide a cash runway into at least the second half of 2028, based on the assumptions used at the time.
- Investors are now watching for commercial progress around P140, further intellectual-property developments and execution of the Kapiglucagon development programme.
Why Is ImmuPharma — LSE:IMM in Focus Today?
ImmuPharma plc — LSE:IMM is in focus on September 24, 2026, after its shares fell 17.04% in the trading data provided.
The decline comes despite several important developments across the company's pipeline during September. ImmuPharma remains a development-stage healthcare company, meaning its valuation is particularly sensitive to scientific progress, intellectual-property developments, clinical and regulatory milestones, financing and potential commercial partnerships.
The company's latest major update package included its half-year financial results, an international patent filing for P140 and new peer-reviewed research. These developments have increased the amount of information investors are assessing around the company's two principal assets.
What Is Driving Investor Attention Around LSE:IMM?
The biggest focus remains P140, ImmuPharma's lead technology platform.
The company is developing P140 around autoimmune disease and is also pursuing a Type M precision-medicine approach, designed to identify a biologically defined patient population that could have a greater likelihood or magnitude of response.
During the first half of 2026, ImmuPharma generated additional experimental data supporting this strategy. The company subsequently incorporated that work into an international patent application covering P140 and the Type M approach.
For investors following LSE:IMM, intellectual-property protection is particularly important because the potential commercial value of a development-stage biotechnology platform depends heavily on the ability to establish and protect differentiated technology.
Why Is the P140 Patent Update Important?
ImmuPharma filed an international Patent Cooperation Treaty application relating to P140 and the Type M precision-medicine approach in September.
The filing represents the next stage of the company's strategy to obtain broader international protection for intellectual property generated through its P140 research programme.
The company has also previously received a Combined Search and Examination Report relating to its UK patent application filed in August 2025.
Investors will therefore be watching how the intellectual-property programme develops, including examination progress, additional data and the potential impact of stronger patent protection on future partnering discussions.
Could P140's Wider Research Applications Increase Interest in LSE:IMM?
P140 is primarily being developed around autoimmune disease, but recent scientific research has expanded the potential areas in which its biological activity is being investigated.
In June, research from the University of Murcia examined P140 in relation to glioblastoma. More recently, research from CNRS and the University of Strasbourg reported P140 activity in a preclinical model of metabolic dysfunction-associated steatohepatitis, or MASH.
These are preclinical research findings and do not establish clinical efficacy in patients. However, they are relevant to the company's broader scientific strategy because they provide additional data concerning the biological activity of P140 outside its original lupus-focused development setting.
For LSE:IMM, investors will be watching whether such research ultimately contributes to additional development opportunities or strengthens the company's partnering proposition.
Why Is a P140 Commercial Deal Important for ImmuPharma?
Commercial partnering is another major catalyst.
ImmuPharma has said it continues to engage with Avion Pharmaceuticals, its US licensing partner for P140. The company has described discussions as constructive and has stated that securing a value-enhancing commercial deal for P140 remains a key objective during 2026.
A commercial agreement could potentially provide greater clarity around the economic value of the P140 programme, although the terms, timing and structure of any future transaction remain uncertain.
Until a definitive commercial arrangement is announced, investors are likely to continue monitoring Partnership discussions as a major potential catalyst for LSE:IMM.
What Is Happening With Kapiglucagon?
Kapiglucagon is the second major programme attracting investor attention.
During the first half of 2026, ImmuPharma moved Kapiglucagon from development planning into active execution. The company has established regulatory, manufacturing, nonclinical and bioanalytical workstreams designed to advance the programme towards IND-enabling development and eventual first-in-human studies.
The company has selected specialist partners for different stages of development, including API manufacturing, drug-product development and bioanalytical work.
ImmuPharma also selected the Kymos Group as its bioanalytical development partner in August, while other Manufacturing and development partnerships had already been established earlier in 2026.
The transition from planning to execution is therefore an important development for LSE:IMM.
What Do the Latest Financial Results Tell Investors?
ImmuPharma remains a development-stage business, so financial performance needs to be viewed alongside Research and Development milestones.
For the six months ended June 30, 2026, the company reported an operating loss of £1.1 million, compared with £1.2 million during the same period in 2025. Research and development expenditure fell to approximately £0.6 million from £0.7 million, while administrative expenses remained around £0.4 million.
The overall reported loss increased to approximately £4.7 million, compared with £1.9 million a year earlier. The company attributed the increase primarily to a £3.36 million finance loss resulting from the fair-value calculation of a derivative financial asset.
This distinction is important because the larger headline loss was not driven solely by increased operating expenditure.
How Important Is ImmuPharma's Cash Position?
Funding remains a key consideration for development-stage healthcare companies.
ImmuPharma completed a fundraising of approximately £6.47 million in April 2026. Management said the financing, together with existing funding, was expected to provide a cash runway to at least the second half of 2028 based on the assumptions used when the financing was completed.
That provides the company with a longer development window for P140 and Kapiglucagon, although future cash requirements can change as programmes advance.
Investors will therefore continue to monitor cash expenditure, development costs and the pace at which the company progresses towards commercial or partnering milestones.
What Could Move ImmuPharma — LSE:IMM Next?
The major potential catalysts include:
- P140 commercial partnering: Further progress with potential commercial arrangements could materially affect investor expectations.
- Patent developments: Examination and international intellectual-property developments remain important for the P140 platform.
- Kapiglucagon development: Progress towards IND-enabling studies and eventual first-in-human development will be closely watched.
- Regulatory interactions: Future discussions with regulators could provide additional clarity around Kapiglucagon's development pathway.
- Scientific data: Additional research concerning P140 could influence the potential scope of the technology.
- Cash runway: Investors will monitor whether available funding remains sufficient as development activity increases.
- Pipeline execution: The ability to advance both programmes while controlling expenditure will remain central to the company's outlook.
Why Are Investors Watching LSE:IMM After Today's 17.04% Fall?
The 17.04% decline on September 24, 2026 puts renewed attention on ImmuPharma's valuation at a time when the company has several potentially important development catalysts.
The recent share-price performance has also been volatile. Historical trading data shows sizeable daily movements throughout September, including gains and declines exceeding 10% on several occasions.
That Volatility is consistent with the characteristics of a small development-stage healthcare company, where expectations can change quickly around scientific developments, financing and commercial partnerships.
Today's decline should therefore be viewed in the context of the company's broader pipeline and upcoming milestones rather than as evidence of a single newly announced negative clinical event.
What Is the Main Issue for ImmuPharma — LSE:IMM Going Forward?
The central focus for ImmuPharma — LSE:IMM is execution.
The company needs to continue strengthening the P140 intellectual-property package, advance commercial discussions and move Kapiglucagon through its development pathway while maintaining sufficient financial resources.
The latest September updates provide evidence of activity across both programmes, but the Investment story remains heavily dependent on future milestones. P140 remains the lead asset, while Kapiglucagon is moving into a more active development phase.
The next major areas to watch are therefore commercial partnering, patent progress, Kapiglucagon development, regulatory milestones and cash utilisation.






Please wait processing your request...